Zhongchao Stock Price, News & Analysis

Zhongchao Inc. (NASDAQ: ZCMD) is an offshore holding company incorporated in the Cayman Islands. Through a series of contractual arrangements, it consolidates the financial results of Zhongchao Medical Technology (Shanghai) Limited and its subsidiaries in China (the “PRC operating entities”). Zhongchao is described as a platform-based internet technology company that focuses on services for patients with oncology and other major diseases, as well as healthcare information and education for medical professionals.

The company’s activities center on two broad areas: services for patients facing cancer and other serious conditions, and professional education and information services for healthcare providers. According to multiple company announcements, Zhongchao’s PRC operating entities provide online healthcare information, professional training, and educational services to healthcare professionals under the “MDMOOC” platform. They also operate patient management and assistance programs in tumor and rare disease fields, internet healthcare services, pharmaceutical services, and an online health information platform for the general public.

Corporate structure and operating model

Zhongchao Inc. is a Cayman Islands exempted company that consolidates the operations of its PRC operating entities through contractual arrangements. These entities include Zhongchao Medical Technology (Shanghai) Limited and subsidiaries such as Shanghai Zhongxin Medical Technology Co., Ltd. (“Zhongxin”), Zhixun Internet Hospital, Xinjiang Medical (also referred to as Xinjiang Pharmaceutical in news releases), and platforms such as Sunshine Health Forums. This structure allows Zhongchao to present consolidated financial results while the underlying operations are carried out in mainland China.

The company’s shares trade on the Nasdaq Capital Market under the symbol “ZCMD”. Zhongchao has used equity incentive plans and has filed related documentation with the U.S. Securities and Exchange Commission (SEC), as reflected in its Form 6-K reports that incorporate financial statements and describe equity compensation arrangements.

Healthcare professional education and digital platforms

A core part of Zhongchao’s business is online healthcare information and education for professionals. Under the “MDMOOC” platform, the PRC operating entities provide professional training and educational services to healthcare professionals. Company disclosures describe the launch of a Digital Online Education Platform for Common Diseases Clinical Diagnosis and Treatment, designed to improve clinical decision-making and patient service capabilities for common and chronic diseases such as cardiovascular and cerebrovascular diseases, cancer, chronic respiratory diseases, and diabetes.

The Digital Online Education Platform is described as following clinical practice guidelines, standardizing diagnostic and treatment behaviors, and facilitating experience sharing among physicians. It enables physicians to access educational content via computers, tablets, and mobile phones. According to Zhongchao, the platform covers 19 disciplines, including cardiology, respiratory medicine, gastroenterology, infectious disease, rheumatology and immunology, nephrology, hematology, endocrinology, neurology, psychiatry, vascular surgery, orthopedics, urology, neurosurgery, obstetrics and gynecology, otolaryngology, hepatology, pediatrics, and parenteral nutrition, with many of these disciplines involving major diseases such as cancer.

In addition to professional education, Zhongchao has engaged in health knowledge popularization for the wider public. Through its Sunshine Health Forums platform and collaborations with partners, it produces and distributes healthcare and medical-related content aimed at improving public health literacy.

Patient management and assistance services

Zhongchao’s PRC operating entities provide patient management services in the professional field of tumor and rare diseases through Zhongxin. These services are described in company news as including disease management, medication assistance, disease follow-up visits, medication management, and health education for patients with cancer and other major diseases.

For breast cancer patients in China, Zhongchao reported that it has provided disease management services since 2021, in collaboration with hospitals, pharmacies, pharmaceutical enterprises, non-profit organizations, and insurance companies. The company states that these services include drug aids, disease follow-up visits, medication management, and cancer education, with a dedicated service team offering patient inquiries, medication assistance, medication usage and experience tracking, and sustained follow-up and management via a hotline.

For lung cancer patients, Zhongchao has introduced a Patient-Reported Outcome (PRO)-based symptom management model. According to the company, this model emphasizes collecting and analyzing patient-reported data on physical symptoms, emotional states, self-perceptions, and other aspects, with the goal of refining management methods and improving patients’ quality of life. Existing patient management services for lung cancer patients are described as including expert-led seminars, mobile application-based educational content, disease follow-up visits, lifestyle advice, drug aids information, and other support services, supported by follow-up channels such as telephones, WeChat, and text messages staffed by disease management specialists.

Zhongxin has also implemented medication assistance projects for patients with systemic lupus erythematosus (SLE). According to a company announcement, Zhongxin has provided medication assistance services to over 7,000 low-income SLE patients in China, distributing approximately 130,000 units of medications such as Titazepam and Belimumab used for SLE treatment. These projects use Zhongxin’s self-developed technical service platform to connect hospitals, pharmacies, corporations, and non-profit organizations, and to provide medication assistance, disease follow-ups, medication management, and health education services.

Collaborations with public health foundations and non-profit organizations

Zhongchao’s PRC operating entities have entered into service agreements with public health foundations in China to support patient aid projects. For example, Zhongxin has worked with the Beijing Public Health Foundation (BPHF), a non-profit organization, on patient aid projects that provide free medications to low-income cancer patients.

One project described by the company donates Doxorubicin Hydrochloride Liposome Injections to low-income patients with breast cancer, lymphoma, Kaposi’s sarcoma, ovarian cancer, osteosarcoma, and myeloma. The project operates through hundreds of hospitals and pharmacies, where qualified patients can receive medications for free after assessment. Zhongxin’s role includes staff training, daily operation management, maintaining the project website, patient management, and monitoring and analyzing project progress using its patient assistance program technical service platform.

Another project with BPHF focuses on donating Trilaciclib Hydrochloride to low-income cancer patients undergoing chemotherapy, with the aim of protecting bone marrow during chemotherapy, mitigating chemotherapy-related adverse reactions, and improving the safety of chemotherapy. Zhongxin is responsible for developing the project’s information system, verifying patients’ medical and economic conditions, recruiting qualified patients, managing drug circulation, addressing patient questions, and providing related support, while BPHF oversees supervision and overall management.

Internet healthcare and pharmaceutical services

According to the company’s repeated descriptions in its news releases, Zhongchao’s PRC operating entities also offer internet healthcare services through Zhixun Internet Hospital and pharmaceutical services through Xinjiang Medical. Xinjiang Medical (also referenced as Xinjiang Pharmaceutical) has introduced and distributed pharmaceutical products in China.

One example disclosed by Zhongchao is Naiditawei®, an anti-influenza drug imported from Natco Pharma Limited in India, commonly known as Oseltamivir Phosphate Capsules. The company states that Xinjiang Pharmaceutical successfully integrated Naiditawei® into the listed online procurement scope of medical treatment drugs across multiple provinces, districts, and cities in China. Naiditawei® is described as belonging to a medical insurance category in China and being part of the national anti-influenza reserve drugs, with different dosage sizes available for the domestic medical market.

The listed online procurement program referenced by Zhongchao is described as an online trading platform for drug tendering and procurement used by public medical institutions and other medical insurance-designated entities. By participating in this program, Xinjiang Pharmaceutical’s product Naiditawei® becomes accessible to a wide range of medical institutions, which the company expects to contribute positively to influenza treatment supply.

Public health communication and audio education initiatives

Zhongchao’s activities also extend to public health communication through partnerships with media platforms. The company has announced a strategic cooperation agreement with Shanghai Ximalaya Technology Co., Ltd. (Ximalaya), a widely used Chinese online audio sharing platform. Under this cooperation, Zhongchao’s operating entity Beijing Zhongchao Boya Medical Technology Co., Ltd. (Boya Medical) and Ximalaya plan to focus on health knowledge popularization, disease prevention advocacy, and behavioral intervention, with the stated goal of improving public health literacy.

The cooperation aims to integrate the strengths of both parties: Ximalaya’s online subscription platform, which provides convenience, instant updates, and personalized services, and Boya Medical’s experience in medical education and production of healthcare and medical-related content. The collaboration is expected by the company to support a content ecosystem on Ximalaya’s platform and explore areas such as intellectual property incubation for health-focused streamers, copyright development, media operations, and brand co-creations.

In a related initiative, Zhongchao has launched an audio course series for cancer education on Ximalaya titled “Let’s Talk About Tumors.” The series is presented by medical professionals from Grade A Tertiary Hospitals and is designed to enhance patients’ and the public’s understanding of cancer, including treatment, daily care, and medication guidance. The company notes that the audio format is intended to be accessible for older cancer patients who may have difficulty with visual content. The first season consists of multiple episodes addressing topics such as immunotherapy, living with cancer, nutritional treatment, and precancerous lesions, with the aim of elevating health literacy in the cancer community.

Regulatory reporting and capital market activities

Zhongchao files periodic reports with the SEC as a foreign private issuer under the Securities Exchange Act of 1934. Form 6-K filings referenced in the input data show that the company furnishes unaudited interim consolidated financial statements and related operating and financial review and prospects, and incorporates these into registration statements on Form S-8 and Form F-3. These filings indicate that Zhongchao uses U.S. capital markets for purposes such as equity compensation and potential securities offerings.

In addition, the company has adopted equity incentive plans. A Form 6-K describes the adoption of a 2025 Equity Incentive Plan, which allows for discretionary grants of options, share appreciation rights, restricted shares, restricted share units, performance units, and performance shares to employees, directors, and consultants. The filing notes that Zhongchao, as a foreign private issuer, may follow Cayman Islands practices in lieu of certain Nasdaq rules, including exemptions from some shareholder approval requirements under Nasdaq Rule 5635, based on advice from its Cayman Islands counsel.

Zhongchao has also undertaken capital structure adjustments related to its Nasdaq listing. A company announcement describes a 1-for-10 share consolidation of its ordinary shares, approved by shareholders and the board of directors, with the objective of regaining compliance with Nasdaq Marketplace Rule 5550(a)(2) and maintaining its listing on the Nasdaq Capital Market. Following the consolidation, the company’s Class A ordinary shares continued to trade under the symbol ZCMD with a new CUSIP number, and the consolidation affected all shareholders uniformly, subject to rounding for fractional shares.

Focus on oncology and major diseases

Across its various platforms and initiatives, Zhongchao consistently describes its focus as serving patients with oncology and other major diseases. The company’s patient management projects, medication assistance programs, and educational initiatives emphasize cancer, rare diseases, and chronic conditions such as SLE. Its digital education platforms for physicians cover major chronic diseases and multiple specialties, many of which are directly related to oncology and complex disease management.

Through collaborations with public health foundations, hospitals, pharmacies, pharmaceutical enterprises, non-profit organizations, and media platforms, Zhongchao positions its PRC operating entities as participants in patient support, medication access, professional education, and public health communication within the Chinese healthcare environment, as described in the company’s own disclosures.